This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ecolab's Set to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
ECL third-quarter results are likely to reflect continued segmental strength.
Cardinal Health to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Despite recent supply chain challenges, new facilities and the acquisition of Specialty Networks are likely to have driven CAH's growth
Do Options Traders Know Something About Acadia (ACAD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Acadia (ACAD) stock based on the movements in the options market lately.
Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?
by Zacks Equity Research
DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.
What's in Store for West Pharmaceutical in Q3 Earnings?
by Zacks Equity Research
WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.
Will FARAPULSE Line Aid Boston Scientific's Q3 Earnings?
by Zacks Equity Research
BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.
Why Acadia (ACAD) Could Beat Earnings Estimates Again
by Zacks Equity Research
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Edwards Lifesciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third quarter.
Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus
by Zacks Equity Research
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.
DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.
Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock
by Zacks Equity Research
LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
by Zacks Equity Research
Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
by Zacks Equity Research
AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.
ACAD or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ACAD vs. TECH: Which Stock Is the Better Value Option?
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
by Zacks Equity Research
Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
by Zacks Equity Research
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
by Zacks Equity Research
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity. Stiff competition in the target market is a woe.
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
by Zacks Equity Research
Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 25% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.